PBI 1402

Drug Profile

PBI 1402

Alternative Names: PBI-1402

Latest Information Update: 22 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProMetic Life Sciences
  • Class Chemoprotectants; Colony-stimulating factors
  • Mechanism of Action Colony stimulating factor stimulants; Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Anaemia
  • No development reported Kidney disorders

Most Recent Events

  • 22 Sep 2015 Phase-I/II development was completed for Anaemia in Canada and Eastern Europe
  • 18 Oct 2010 PBI 1402 licensed to Allist Pharmaceuticals in China
  • 13 Jun 2010 Preclinical pharmacodynamics data presented at the 15th Congress of the European Hematology Association (EHA-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top